Wearable Injectors and Connected Devices Conference 2019

SMi is proud to present the inaugural Wearable Injectors and Connected DevicesConference, taking place on the 9th-10th October 2019, in London. The global wearable devices market size is expected to reach a value of $12.1 billion USD by 2021 with time dependent delivery, large volume administration with minimal injection pain and the use of connectivity to enhance user-value being key factors driving the market.

Spotlight


OTHER PAST CONFERENCES

Pharma Contract Manufacturing Conference Europe

April 9-11, 2024 | Germany

Welcome To The Industry’s Leading Pharma Contract Manufacturing Event. Pharma Contract Manufacturing is the only event to focus specifically on how to improve CMO selection and partnering. We appreciate the critical role these play in delivering success for both patients and the organisation-at-large. We also appreciate that the bedrock of these relationships is collaboration from both sides, which is why we bring together leading pharmaceutical companies and CMOs to benchmark best practice in this area. Selecting the right CMO partner is the critical decision in getting high-quality products to patients. If this relationship fails, we fail. Our companies and patients can’t afford for us to get this decision wrong. That’s why Pharma IQ is bringing together partners from across the industry to collaborate on how we make these relationships work both now and in the future. Because for the patient to succeed, we need to succeed.

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

May 13-16, 2024 | USA

The 2024 AAPS National Biotechnology Conference, scheduled for May 13-16, 2024, at the Hilton San Francisco Union Square in California, is set to be a pivotal event in the field of biotechnology. This conference aims to bring together experts and researchers to discuss and explore the latest advancements in biotechnology, focusing on the discovery, formulation, and delivery of new modalities. The event is structured around two main tracks, each encompassing multiple themes that address the forefront of biotechnological research and development. Track 1 delves into the advances in discovery, formulation, and delivery of new modalities, particularly in the biologics market. It invites submissions on a wide range of topics, including multi-specific antibodies, oligonucleotides, proteins, nanobodies, genes, RNA, peptides, cell-free manufactured proteins, vaccines, and various types of cells. The track emphasizes the importance of innovative strategies in addressing unmet medical needs through these modalities. The conference also features a second track focusing on novel strategies to advance biotherapeutic development, with themes that cover a broad spectrum of current biotechnological challenges and innovations. This includes preformulation and formulation approaches for biologics, drug delivery systems for new modalities and therapies, and the transformative role of AI/ML in drug discovery and development. Additionally, the conference will address the development strategies for novel targeted therapeutic delivery, advances in analytical and bioanalytical platform technology, and high content bioanalysis. These discussions are expected to cover cutting-edge topics such as targeted drug delivery systems, analytical platform technologies, and the integration of artificial intelligence and machine learning in drug development. Overall, the 2024 AAPS National Biotechnology Conference represents a significant gathering for the biotechnology community, offering a platform for the exchange of ideas and fostering collaborations in the pursuit of advancing biotechnological research and applications.

National Medtech & Biotech Summit 2024

May 28-29, 2024 | Ireland

Ireland is now a well-established global leader in MedTech and Biotechnology. Nine of the world’s top ten MedTech companies have a base in Ireland. Indeed, Ireland is one of the top seven employers of MedTech professionals in Europe, with more than 40,000 people currently working in the sector. Furthermore, there are now more than 450 MedTech companies operating in Ireland with over 60% having been developed locally. In the Biotechnology sector, there are well over 300 companies operating in Ireland. Indeed, all but one of the world’s 25 largest Biotech and Pharma companies have a presence in Ireland. In recent years, capital investment of about $10 billion has been made in new facilities by the BioPharma industry in Ireland. This is believed to represent close to the biggest wave of investment in new BioTech facilities anywhere in the world, according to the IDA Ireland (Ireland’s inward investment promotion agency). The Biotechnology Innovation Organisation defines Biotechnology at its simplest as technology based on biology – Biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the health of our planet. Medical Technologies relate to prevention, diagnosis, monitoring, treatment, and care, and often utilise new technologies such as artificial intelligence or machine learning, according to MedTech Europe. The National MedTech & Biotech Summit, which is being held on 28th - 29th May 2024 at the RDS Simmonscourt, in Dublin, will highlight the key trends and challenges facing the sector, while also showcasing the latest innovations and developments in best practice, and the technological solutions available. The event will focus on the global growth opportunities, as well as major trends such as digital health and the shift to value-based healthcare and the long-term implications for manufacturers and business models.

AI x PHARMA x HEALTH 2024

March 27, 2024 | Finland

Welcome to learn about artificial intelligence (AI) and its transformative impact on the pharmaceutical industry and healthcare at AI x PHARMA x HEALTH 2024!